Compare BOOM & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOM | CUE |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 124.5M |
| IPO Year | 1995 | 2017 |
| Metric | BOOM | CUE |
|---|---|---|
| Price | $5.93 | $32.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.50 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 384.9K | 126.7K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.02 | 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $609,840,000.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $4.69 | $0.17 |
| 52 Week High | $9.20 | $45.50 |
| Indicator | BOOM | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 55.04 |
| Support Level | $5.55 | $24.49 |
| Resistance Level | $6.50 | $32.82 |
| Average True Range (ATR) | 0.29 | 4.44 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 4.30 | 35.05 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.